Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.

J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.

2.

New name for breast-cancer syndrome could help to save lives.

Pritchard CC.

Nature. 2019 Jul;571(7763):27-29. doi: 10.1038/d41586-019-02015-7. No abstract available.

PMID:
31270479
3.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

4.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

5.

Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL.

J Pathol. 2019 Sep;249(1):79-89. doi: 10.1002/path.5283. Epub 2019 May 24.

PMID:
30993692
6.

Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome.

Pearlman R, Haraldsdottir S, de la Chapelle A, Jonasson JG, Liyanarachchi S, Frankel WL, Rafnar T, Stefansson K, Pritchard CC, Hampel H.

J Med Genet. 2019 Jul;56(7):462-470. doi: 10.1136/jmedgenet-2018-105698. Epub 2019 Mar 15.

PMID:
30877237
7.

Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.

Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC.

Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13.

PMID:
30865311
8.

Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology.

Cohen SA, Pritchard CC, Jarvik GP.

Annu Rev Genomics Hum Genet. 2019 Aug 31;20:293-307. doi: 10.1146/annurev-genom-083118-015406. Epub 2019 Mar 8.

PMID:
30848956
9.

The effects of genomic germline variant reclassification on clinical cancer care.

Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN.

Oncotarget. 2019 Jan 11;10(4):417-423. doi: 10.18632/oncotarget.26501. eCollection 2019 Jan 11.

10.

DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.

Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.

Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.

PMID:
30636012
11.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.

J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.

PMID:
30625039
12.

BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00115. Epub 2018 Jun 29. No abstract available.

13.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

14.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

15.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

16.

Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova G, Liu F, Raoul A, Cao H, Romero IL, Hong S, Livingston R, Jaskowiak N, Wang X, Debiasi M, Pritchard CC, King MC, Karczmar G, Newstead GM, Huo D, Olopade OI.

Clin Cancer Res. 2019 Mar 15;25(6):1786-1794. doi: 10.1158/1078-0432.CCR-18-0200. Epub 2018 Aug 28.

PMID:
30154229
17.

Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.

Piacitelli AM, Jensen DM, Brandling-Bennett H, Gray MM, Batra M, Gust J, Thaker A, Paschal C, Tsuchiya K, Pritchard CC, Perkins J, Mirzaa GM, Bennett JT.

Am J Med Genet A. 2018 Nov;176(11):2301-2308. doi: 10.1002/ajmg.a.40487. Epub 2018 Jul 31.

PMID:
30063105
18.

A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing.

Wehr C, Grotius K, Casadei S, Bleckmann D, Bode SFN, Frye BC, Seidl M, Gulsuner S, King MC, Percival MB, Pritchard CC, Walsh T, Wu D, Keel S, Salzer U.

Blood. 2018 Sep 13;132(11):1211-1215. doi: 10.1182/blood-2018-03-837336. Epub 2018 Jul 20. No abstract available.

19.

Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.

Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, Hampel H, Frankel WL.

Mod Pathol. 2018 Dec;31(12):1891-1900. doi: 10.1038/s41379-018-0058-y. Epub 2018 Jul 2.

PMID:
29967423
20.

A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.

Zhao S, Leonardson A, Geybels MS, McDaniel AS, Yu M, Kolb S, Zong H, Carter K, Siddiqui J, Cheng A, Wright JL, Pritchard CC, Lance R, Troyer D, Fan JB, Ostrander EA, Dai JY, Tomlins SA, Feng Z, Stanford JL.

Prostate. 2018 Jun 28. doi: 10.1002/pros.23667. [Epub ahead of print]

21.

Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Shirts BH, Konnick EQ, Upham S, Walsh T, Ranola JMO, Jacobson AL, King MC, Pearlman R, Hampel H, Pritchard CC.

Am J Hum Genet. 2018 Jul 5;103(1):19-29. doi: 10.1016/j.ajhg.2018.05.001. Epub 2018 Jun 7.

22.

Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Herman DS, Smith C, Liu C, Vaughn CP, Palaniappan S, Pritchard CC, Shirts BH.

J Mol Diagn. 2018 Jul;20(4):512-521. doi: 10.1016/j.jmoldx.2018.03.010. Epub 2018 May 22.

23.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

24.

Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

Hemminger JA, Pearlman R, Haraldsdottir S, Knight D, Jonasson JG, Pritchard CC, Hampel H, Frankel WL.

Hum Pathol. 2018 Aug;78:125-130. doi: 10.1016/j.humpath.2018.04.017. Epub 2018 May 1.

25.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

26.

Corrigendum: Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525a.

PMID:
29634692
27.

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.

Waalkes A, Smith N, Penewit K, Hempelmann J, Konnick EQ, Hause RJ, Pritchard CC, Salipante SJ.

Clin Chem. 2018 Jun;64(6):950-958. doi: 10.1373/clinchem.2017.285981. Epub 2018 Apr 9.

28.

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, Shirts BH, Pritchard CC; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2018 Jun 1;4(6):806-813. doi: 10.1001/jamaoncol.2018.0104.

29.

Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U.

Cancer Discov. 2018 Jun;8(6):730-749. doi: 10.1158/2159-8290.CD-17-1327. Epub 2018 Mar 6.

30.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.

Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.

31.

DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.

Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.

Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6. No abstract available.

PMID:
29287968
32.

Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations.

Cole BL, Pritchard CC, Anderson M, Leary SE.

Pediatr Dev Pathol. 2018 Jul-Aug;21(4):380-388. doi: 10.1177/1093526617743905. Epub 2017 Nov 27.

PMID:
29173061
33.

Corrigendum: Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2017 Oct 6;23(10):1241. doi: 10.1038/nm1017-1241a.

PMID:
28985213
34.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

35.

Prostate Cancer Screening in a New Era of Genetics.

Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.

Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Review.

PMID:
28697982
36.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

37.

Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.

Friedlander TW, Pritchard CC, Beltran H.

Am Soc Clin Oncol Educ Book. 2017;37:358-369. doi: 10.14694/EDBK_175510. Review.

PMID:
28561699
38.

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.

Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, Bekaii-Saab T, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K.

Nat Commun. 2017 May 3;8:14755. doi: 10.1038/ncomms14755.

39.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, Peretz T, Goldberg Y.

Gastroenterology. 2017 Jun;152(8):1876-1880.e1. doi: 10.1053/j.gastro.2017.02.014. Epub 2017 Feb 24.

PMID:
28242209
40.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2017 Apr 1;3(4):464-471. doi: 10.1001/jamaoncol.2016.5194.

41.

DNA-Repair Gene Mutations in Metastatic Prostate Cancer.

Pritchard CC, Offit K, Nelson PS.

N Engl J Med. 2016 Nov 3;375(18):1804-5. doi: 10.1056/NEJMc1611137. No abstract available.

PMID:
27806229
42.

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T, Shimamura A.

Haematologica. 2016 Nov;101(11):1343-1350. Epub 2016 Jul 14.

43.

Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2016 Nov;22(11):1342-1350. doi: 10.1038/nm.4191. Epub 2016 Oct 3. Erratum in: Nat Med. 2017 Oct 6;23 (10 ):1241. Nat Med. 2018 Apr 10;24(4):525.

PMID:
27694933
44.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.

Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31. Review.

45.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

46.

Family-Specific Variants and the Limits of Human Genetics.

Shirts BH, Pritchard CC, Walsh T.

Trends Mol Med. 2016 Nov;22(11):925-934. doi: 10.1016/j.molmed.2016.09.007. Epub 2016 Oct 11. Review.

48.

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer.

Nghiem B, Zhang X, Lam HM, True LD, Coleman I, Higano CS, Nelson PS, Pritchard CC, Morrissey C.

Asian J Urol. 2016 Oct;3(4):223-228. doi: 10.1016/j.ajur.2016.09.002. Epub 2016 Sep 12.

49.

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Feb;77(2):123-144. doi: 10.1002/pros.23260. Epub 2016 Sep 28. Review.

PMID:
27679977
50.

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.

Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, Kircher M, Olds C, Juusola J, Collins S, Park K, Carter M, Glass I, Krägeloh-Mann I, Chitayat D, Parikh AS, Bradshaw R, Torti E, Braddock S, Burke L, Ghedia S, Stephan M, Stewart F, Prasad C, Napier M, Saitta S, Straussberg R, Gabbett M, O'Connor BC, Keegan CE, Yin LJ, Lai AHM, Martin N, McKinnon M, Addor MC, Boccuto L, Schwartz CE, Lanoel A, Conway RL, Devriendt K, Tatton-Brown K, Pierpont ME, Painter M, Worgan L, Reggin J, Hennekam R, Tsuchiya K, Pritchard CC, Aracena M, Gripp KW, Cordisco M, Van Esch H, Garavelli L, Curry C, Goriely A, Kayserilli H, Shendure J, Graham J Jr, Guerrini R, Dobyns WB.

JCI Insight. 2016 Jun 16;1(9). pii: 87623. doi: 10.1172/jci.insight.87623.

Supplemental Content

Loading ...
Support Center